Evidence map›Paper›PMID 40338225›Full record

ArticleeLife2025

HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity.

Karen Giménez-Orenga, Eva Martín-Martínez, Lubov Nathanson, Elisa Oltra

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karen Giménez-OrengaEscuela de Doctorado, Catholic University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0001-9790-7327
Eva Martín-MartínezNational Health Service, Manises Hospital, Valencia, Spain.ORCID https://orcid.org/0000-0003-3261-494X
Lubov NathansonInstitute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, United States.ORCID https://orcid.org/0000-0003-1038-9083
Elisa OltraDepartment of Pathology, School of Health Sciences, Catholic University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0003-0598-2907

Funding

Generalitat Valenciana ACIF2021/179Generalitat Valenciana CIAICO/2021/103ME Research UK SC036942
6 · The paper itself

Abstract

Research of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM), two acquired chronic illnesses affecting mainly females, has failed to ascertain their frequent co-appearance and etiology. Despite prior detection of human endogenous retrovirus (HERV) activation in these diseases, the potential biomarker value of HERV expression profiles for their diagnosis, and the relationship of HERV expression profiles with patient immune systems and symptoms had remained unexplored. By using HERV-V3 high-density microarrays (including over 350k HERV elements and more than 1500 immune-related genes) to interrogate the transcriptomes of peripheral blood mononuclear cells from female patients diagnosed with ME/CFS, FM, or both, and matched healthy controls (

Indexed as

Endogenous RetrovirusesFatigue Syndrome, ChronicFibromyalgiaVirus ActivationAdultFemaleGene Expression ProfilingHumansLeukocytes, MononuclearMiddle AgedbiomarkerepigeneticsfibromyalgiaHERVhumanimmunologyinfectious diseaseME/CFSmedicinemicrobiology

Identifiers

PMID40338225
PMCPMC12061480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.